Control of cardiovascular risk in patients with diabetes
Prevalence of diabetes mellitus (DM) is a version of pandemic, in Russia as well, nowadays. Mortality of patients suffering from DM is associa-ted with the development of macrovascular complications and successful prevention of these complications depends on the complex approach to identify and to c...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2016-08-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | http://syst-hypertension.ru/en/archive/2016/vol-13-3-2016/control-of-cardiovascular-risk-in-patients-with-diabetes_1921/ |
| _version_ | 1828432460807929856 |
|---|---|
| author | Zhernakova Yu.V. Chazova I.E. |
| author_facet | Zhernakova Yu.V. Chazova I.E. |
| author_sort | Zhernakova Yu.V. |
| collection | DOAJ |
| description | Prevalence of diabetes mellitus (DM) is a version of pandemic, in Russia as well, nowadays. Mortality of patients suffering from DM is associa-ted with the development of macrovascular complications and successful prevention of these complications depends on the complex approach to identify and to correct all modifiable risk factors, included in risk indexes. According to many experts’ point of view, key moments in reducing the risk of cardiovascular complications in patients with DM are to achieve target blood pressure and target levels of lipid metabolism, including the application of non-drug therapies. However, the appearance of new data concerning the possibility of antihyperglycemic therapy, no doubt, will change our point of view on managing cardiovascular risk in patients with DM, in particular empagliflozin, which can influence on cardiovascular outcomes. |
| first_indexed | 2024-12-10T18:20:40Z |
| format | Article |
| id | doaj.art-a35b02ff71e64b9c99e97c4b9fa7b68e |
| institution | Directory Open Access Journal |
| issn | 2075-082X 2542-2189 |
| language | Russian |
| last_indexed | 2024-12-10T18:20:40Z |
| publishDate | 2016-08-01 |
| publisher | IP Morozov P.V. |
| record_format | Article |
| series | Системные гипертензии |
| spelling | doaj.art-a35b02ff71e64b9c99e97c4b9fa7b68e2022-12-22T01:38:13ZrusIP Morozov P.V.Системные гипертензии2075-082X2542-21892016-08-01133424710.26442/2075-082X_13.3.42-47Control of cardiovascular risk in patients with diabetesZhernakova Yu.V.0Chazova I.E.1A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15aA.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15aPrevalence of diabetes mellitus (DM) is a version of pandemic, in Russia as well, nowadays. Mortality of patients suffering from DM is associa-ted with the development of macrovascular complications and successful prevention of these complications depends on the complex approach to identify and to correct all modifiable risk factors, included in risk indexes. According to many experts’ point of view, key moments in reducing the risk of cardiovascular complications in patients with DM are to achieve target blood pressure and target levels of lipid metabolism, including the application of non-drug therapies. However, the appearance of new data concerning the possibility of antihyperglycemic therapy, no doubt, will change our point of view on managing cardiovascular risk in patients with DM, in particular empagliflozin, which can influence on cardiovascular outcomes.http://syst-hypertension.ru/en/archive/2016/vol-13-3-2016/control-of-cardiovascular-risk-in-patients-with-diabetes_1921/arterial hypertensiondiabetes mellitusrisk managementdyslipidemiaempagliflozin |
| spellingShingle | Zhernakova Yu.V. Chazova I.E. Control of cardiovascular risk in patients with diabetes Системные гипертензии arterial hypertension diabetes mellitus risk management dyslipidemia empagliflozin |
| title | Control of cardiovascular risk in patients with diabetes |
| title_full | Control of cardiovascular risk in patients with diabetes |
| title_fullStr | Control of cardiovascular risk in patients with diabetes |
| title_full_unstemmed | Control of cardiovascular risk in patients with diabetes |
| title_short | Control of cardiovascular risk in patients with diabetes |
| title_sort | control of cardiovascular risk in patients with diabetes |
| topic | arterial hypertension diabetes mellitus risk management dyslipidemia empagliflozin |
| url | http://syst-hypertension.ru/en/archive/2016/vol-13-3-2016/control-of-cardiovascular-risk-in-patients-with-diabetes_1921/ |
| work_keys_str_mv | AT zhernakovayuv controlofcardiovascularriskinpatientswithdiabetes AT chazovaie controlofcardiovascularriskinpatientswithdiabetes |